[1]侯梦月,黄金智,张玲莉.SIRT2及其与子宫内膜癌关系的研究进展[J].医学信息,2019,(05):31-34.[doi:10.3969/j.issn.1006-1959.2019.05.012]
 HOU Meng-yue,HUANG Jin-zhi,ZHANG Ling-li.Progress in the Study of SIRT2 and its Relationship with Endometrial Cancer[J].Medical Information,2019,(05):31-34.[doi:10.3969/j.issn.1006-1959.2019.05.012]
点击复制

SIRT2及其与子宫内膜癌关系的研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年05期
页码:
31-34
栏目:
综述
出版日期:
2019-03-01

文章信息/Info

Title:
Progress in the Study of SIRT2 and its Relationship with Endometrial Cancer
文章编号:
1006-1959(2019)05-0031-04
作者:
侯梦月12黄金智2张玲莉2
(1.广东医科大学,广东 湛江 524000;2.广东医科大学附属医院妇科,广东 湛江 524000)
Author(s):
HOU Meng-yue12HUANG Jin-zhi2ZHANG Ling-li2
(1.Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Department of Gynecology,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,Guangdong,China)
关键词:
SIRT2子宫内膜癌信号通路
Keywords:
SIRT2Endometrial cancerSignaling pathway
分类号:
R71
DOI:
10.3969/j.issn.1006-1959.2019.05.012
文献标志码:
A
摘要:
沉默信息调节因子2(SIRT2)属于去乙酰化酶sirtuins家族成员之一,调节广泛的生物学功能,包括衰老、新陈代谢、分化、维持基因组完整性及肿瘤的发生。SIRT2在子宫内膜癌的发生中亦发挥作用,本文就SIRT2的生物学特征、对代谢的影响、在肿瘤发生中的作用及其与子宫内膜癌的关系进行综述,为子宫内膜癌发病机制的研究提供思路,以便更好地进行子宫内膜癌的临床诊治。
Abstract:
Silencing Information Regulator 2 (SIRT2) is a member of the deacetylase sirtuins family that regulates a wide range of biological functions, including aging, metabolism, differentiation, maintenance of genomic integrity, and tumorigenesis. SIRT2 also plays a role in the development of endometrial cancer. This article reviews the biological characteristics of SIRT2, its effects on metabolism, its role in tumorigenesis and its relationship with endometrial cancer, and is the cause of endometrial cancer. Mechanism research provides ideas for better clinical diagnosis and treatment of endometrial cancer.

参考文献/References:


[1]Donmez G,Outeiro TF.SIRT1 and SIRT2:Emerging Targets in Neurodegeneration[J].EMBO Mol Med,2013,5(3):344-352.
[2]张现营.去乙酰化酶Sirt2参与脂类代谢研究[D].华东师范大学,2015.
[3]Masri S.Sirtuin-Dependent Clock Control:New Advances in Metabolism, Aging and Cancer[J].Curr Opin Clin Nutr Metab Care,2015,18(6):521-527.
[4]Vaquero A,Scher MB,Lee DH,et al.SirT2 is a Histone Deacetylase with Preference for Histone H4 Lys 16 During Mitosis[J].Genes Dev,2006,20(10):1256-1261.
[5]North BJ,Verdin E.Interphase Nucleo-Cytoplasmic Shuttling and Localization of SIRT2 During Mitosis[J].PLoS One,2007,2(8):e784.
[6]Dryden SC,Nahhas FA,Nowak JE,et al.Role for Human SIRT2 NAD-dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle[J].Mol Cell Biol,2003,23(9):3173-3185.
[7]吴国芳,路宏朝,贾龙,等.干扰Sirt2促进C2C12成肌细胞分化[J].中国生物化学与分子生物学报,2014,30(7):714-720.
[8]Eijkelenboom A,Burgering BM.FOXOs:Signalling Integrators for Homeostasis Maintenance[J].Nat Rev Mol Cell Biol,2013,14(2):83-97.
[9]Gomes P,Fleming OT,Cavadas C.Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism[J].Trends Pharmacol Sci,2015,36(11):756-768.
[10]Wang F,Tong Q.SIRT2 Suppresses Adipocyte Differentiation by Deacetylating FOXO1 and Enhancing FOXO1’s Repressive Interaction with PPARgamma[J].Mol Biol Cell,2009,20(3):801-808.
[11]Jiang W,Wang S,Xiao M,et al.Acetylation Regulates Gluconeogenesis by Promoting PEPCK1 Degradation Via Recruiting the UBR5 Ubiquitin Ligase[J].Mol Cell,2011,43(1):33-44.
[12]杜燕华,张海燕,孙红.Sirt2在浆液性卵巢癌细胞系中的表达及其对增殖、迁移和侵袭的影响[J].中国病理生理杂志,2015,31(7):1209-1213.
[13]Kim HS,Vassilopoulos A,Wang RH,et al.SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity[J].Cancer Cell,2011,20(4):487-499.
[14]Inoue T,Hiratsuka M,Osaki M,et al.The Molecular Biology of Mammalian SIRT Proteins: SIRT2 in Cell Cycle Regulation[J].Cell Cycle,2007,6(9):1011-1018.
[15]Li Y,Zhang M,Dorfman RG,et al.SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism[J].Neoplasia,2018,20(7):745-756.
[16]Liu PY,Xu N,Malyukova A,et al.The Histone Deacetylase SIRT2 Stabilizes Myc Oncoproteins[J].Cell Death Differ,2013,20(3):503-514.
[17]宋春丽,任吉华,冉龙宽,等.Sirt2沉默对肝癌细胞的迁移和侵袭能力的影响[J].第三军医大学学报,2013,35(24):2634-2638.
[18]王平安.剪接因子Srsf2在肝细胞癌中的作用及Sirt2在肝内胆管癌发生发展中的作用及机制研究[D].山东大学,2018.
[19]Peck B,Chen CY,Ho KK,et al.SIRT Inhibitors Induce Cell Death and P53 Acetylation through Targeting Both SIRT1 and SIRT2[J].Mol Cancer Ther,2010,9(4):844-855.
[20]Kastenhuber ER,Lowe SW.Putting P53 in Context[J].Cell,2017,170(6):1062-1078.
[21]Yue X,Zhao Y,Xu Y,et al.Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy[J].J Mol Biol,2017,429(11):1595-1606.
[22]Rinkenbaugh AL,Baldwin AS.The NF-κB Pathway and Cancer Stem Cells[J].Cells,2016,5(2):E16.
[23]Giampazolias E,Zunino B,Dhayade S,et al.Mitochondrial Permeabilization Engages NF-κB-dependent Anti-Tumour Activity Under Caspase Deficiency[J].Nat Cell Biol,2017,19(9):1116-1129.
[24]吴安定,万里鹏,覃艳琼.结直肠腺癌组织中Cyr61和NF-κB P65的表达及其临床病理意义[J].世界华人消化杂志,2018,26(17):1056-1063.
[25]Chen L,Fischle W,Verdin E,et al.Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation[J].Science,2001,293(5535):1653-1657.
[26]Kiernan R,Bres V,Ng RW,et al.Post-Activation Turn-Off of NF-κB-dependent Transcription is Regulated by Acetylation of P65[J].J Biol Chem,2003,278(4):2758-2766.
[27]Zhou S,Tang X,Chen HZ.Sirtuins and Insulin Resistance[J].Front Endocrinol(Lausanne),2018(9):748.
[28]Paik JH,Kollipara R,Chu G,et al.FoxOs are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis[J].Cell,2007,128(2):309-323.
[29]Jing E,Gesta S,Kahn CR.SIRT2 Regulates Adipocyte Differentiation through FoxO1 Acetylation/Deacetylation[J].Cell Metab,2007,6(2):105-114.
[30]Zhao Y,Yang J,Liao W,et al.Cytosolic FoxO1 is Essential for the Induction of Autophagy and Tumour Suppressor Activity[J].Nat Cell Biol,2010,12(7):665-675.
[31]Du Y,Wu J,Zhang H,et al.Reduced Expression of SIRT2 in Serous Ovarian Carcinoma Promotes Cell Proliferation through Disinhibition of CDK4 Expression[J].Mol Med Rep,2017,15(4):1638-1646.
[32]刘伟,肖俊,兰金芝,等.组蛋白乙酰化水平对肝癌细胞迁移和侵袭能力的影响[J].贵州医科大学学报,2017,42(12):1365-1369.
[33]Das C,Lucia MS,Hansen KC,et al.CBP/p300-mediated Acetylation of Histone H3 On Lysine 56[J].Nature,2009,459(7243):113-117.
[34]Serrano L,Martinez-Redondo P,Marazuela-Duque A,et al.The Tumor Suppressor SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating the Mitotic Deposition of H4K20 Methylation[J].Genes Dev,2013,27(6):639-653.
[35]石斌,王昊,赵亮,等.组蛋白去乙酰化酶抑制剂对肺癌细胞株Mdr1、Mrp1表达的影响及其机制[J].山东医药,2018(39):13-16.
[36]Ebeid K,Meng X,Thiel KW,et al.Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer[J].Nature Nanotechnology,2018,13(1):72-81.
[37]Tran A,Gehrig P.Recent Advances in Endometrial Cancer[J].F1000Research,2017(6):81.
[38]Chen W,Zheng R,Baade PD,et al.Cancer Statistics in China, 2015[J].CA: A Cancer Journal for Clinicians,2016,66(2):115-132.
[39]谢幸.妇产科学[M].第8版.北京:人民卫生出版社,2014:488.
[40]Practice Bulletin No.149: Endometrial Cancer[J].Obstet Gynecol,2015,125(4):1006-1026.
[41]王艺霖.SIRTl/FoxOl/SREBP-1通路在子宫内膜癌孕激素抵抗发展中的作用[D].山东大学,2018.

相似文献/References:

[1]单菲菲,陈 琴,吕建国,等.体力活动与子宫内膜癌关系的病例对照研究[J].医学信息,2018,(10):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
 SHAN Fei-fei,CHEN Qin,LV Jian-guo,et al.Case Control Study on the Relationship between Physical Activity and Endometrial Carcinoma[J].Medical Information,2018,(05):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
[2]季福水.AP-4、EZH2基因表达量与子宫内膜癌病灶中细胞凋亡、 上皮间质转化的相关性研究[J].医学信息,2018,(14):92.[doi:10.3969/j.issn.1006-1959.2018.14.026]
 JI Fu-shui.Correlation between AP-4 and EZH2 Gene Expression Levels and Apoptosis and Epithelial-mesenchymal Transition in Endometrial Cancer[J].Medical Information,2018,(05):92.[doi:10.3969/j.issn.1006-1959.2018.14.026]

更新日期/Last Update: 2019-03-01